Determination of ceftazidime and cefepime in plasma and dialysate-ultrafiltrate from patients undergoing continuous veno-venous hemodiafiltration by HPLC

Determination of ceftazidime and cefepime in plasma and dialysate-ultrafiltrate from patients undergoing continuous veno-venous hemodiafiltration by HPLC
July 18, 2005
A. Isla, a, A. Arzuaga, a, J. Maynar, b, A.R. Gasc?n, a, M.A. Solin?s, a, E. Corral, b and J.L. Pedraz, a
aLaboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Paseo de la Universidad no. 7, 01006 Vitoria-Gasteiz, Spain
bIntensive Care Unit, Santiago Ap?stol Hospital, Vitoria-Gasteiz, Spain
Journal of Pharmaceutical and Biomedical Analysis
You can view the abstract online. A subscription is required to view the full text or it can be purchased online.
We have developed and validated a new, rapid and reproducible HPLC method for the determination of cefepime and ceftazidime in plasma and dialysate-ultrafiltrate samples obtained from intensive care unit (ICU) patients undergoing continuous veno-venous hemodiafiltration (CVVHDF). The method for plasma samples involved protein precipitation with acetonitrile, followed by washing with dichloromethane to remove apolar lipophilic compounds. Dialysate-ultrafiltrate samples did not require any preparation. Separation was performed on a ?Bondapak C18 (30 cm ? 3.9 mm ? 10 ?m) with UV detection. The mobile phase contained acetate buffer: ACN and was delivered at 2 ml/min. The coefficients of determination of the calibration curves were always =0.998 and R.S.D.% of the response factors <10%. The intra and inter-assay precision and accuracy of the quality controls (QC) and limit of quantification (LOQ) were satisfactory in all cases. Plasma and dialysate-ultrafiltrate samples were stable at -20 and -80 ?C for 2 months and also after three freeze/thaw cycles. Dialysate-ultrafiltrate samples were stable in the chromatographic rack for 24 h at room temperature, but we recommend storing processed plasma samples at 4 ?C until the analysis. The described method has proved to be useful to give accurate measurements of ceftazidime and cefepime in samples obtained from patients undergoing CVVHDF.